Supported by AstraZeneca

Not For Credit

Presented by:
Reynold A Panettieri, MD

This program will examine the relationship between shortacting 2-agonist (SABA) reliance, patient behavior, and asthma morbidity. An understanding of SABA reliance and its consequences highlights an unmet need and an opportunity to optimize control.

Also visit AstraZeneca at Booth #301.

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Not For Credit

Presented by:
Neal Jain, MD

Listen to an expert clinician discussion an add-on maintenance treatment for patients with moderateto- severe asthma aged 12 years and older with an eosinophilic phenotype or oral corticosteroid-dependent asthma. Our presenter will highlight key roles for Type 2 Inflammation in the pathobiology of asthma and the efficacy and safety data across three clinical trials in nearly 3,000 patients with asthma. Additionally, our presenter will lead an interactive discussion of different patient types who might be eligible for treatment.

Also visit Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. at Booth #313.

Supported by GlaxoSmithKline

Not For Credit

Presented by:
Dennis K. Ledford, MD

Join us for an engaging program exploring the role of eosinophils in disease management. We will examine key efficacy and safety data for a treatment that reduces eosinophils, including long-term data in patients with severe asthma. We will also discuss clinical approaches for identifying appropriate patient types that may benefit from a targeted treatment to reduce eosinophils.

Also visit GlaxoSmithKline at Booth #1012.

Supported by AstraZeneca

Not For Credit

Presented by:
Warner Carr, MD

Please join us to learn more about ways to help identify eosinophilic asthma through a combination of clinical features, patient history and measurements of eosinophils told through three compelling patient case studies. Hosted by a national expert, explore a targeted treatment approach for patients with both efficacy and safety profile data.

Also visit AstraZeneca at Booth #301.

Supported by CSL Behring

Not For Credit

Presented by:
Raffi Tachdjian , MD, MPH
Zahra Khan (HAE Patient Advocate)

Join us as we present newly published data from the Open Label Extension Study following patients long term. Hear from an HAE opinion leader and an HAE patient as they talk about the impact of HAE and successfully managing the disease.

Also visit CSL Behring at Booth #123.

Supported by Novartis Pharmaceuticals Corporation

Not For Credit

Allergic asthma is a specific phenotype of a common disease with wide heterogeneity. Associated comorbidities often go hand-in-hand with the condition. Such comorbidities may share common immunopathological mechanisms with asthma that can influence its control. Immune Response Pathways: Characteristics of Asthma and Comorbidities will focus on the immune response of allergic asthma, accurate recognition of these characteristics and proper management of comorbidities.

Also visit Novartis Pharmaceuticals Corporation at Booth #1213.

Supported by Optinose

Not For Credit

Presented by:
Shahnaz Fatteh, MD

Explore a unique patient case to understand how XHANCE is a different treatment approach.

Also visit Optinose at Booth #1021.

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Not For Credit

Presented by:
Eli O. Meltzer, MD

Please join Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. for a Product Theater presentation at the ACAAI Conference, located on the exhibit floor. Food and beverage to be served.

Supported by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., Booth #313

Supported by Pfizer, Inc.

Not For Credit

Presented by:
Ankmalika Gupta, MD

Join us for an interactive presentation on a steroid-free topical therapy for the treatment of mild-to-moderate atopic dermatitis. Expert faculty will guide the audience through an in-depth look into the product and answer questions to help attendees gain a better understanding of this treatment option.

Also visit Pfizer, Inc. at Booth #1013.

Supported by AstraZeneca

Not For Credit

Presented by:
Reynold A Panettieri, MD

Join us for an educational program exploring the mechanistic role of eosinophils in severe asthma. This interactive presentation will review updated guidance in assessing severe asthma, examine the role of eosinophils in severe asthma, and highlight the impact of oral corticosteroid (OCS) use in severe uncontrolled asthma.

Also visit AstraZeneca at Booth #301.

Not For Credit

Presented by:
Jonathan A. Bernstein, MD
Lawrence D. Sher, MD

Come learn about clinical efficacy, safety information, MOA, and dosing and administration, and how DUPIXENT may help your patients.
 

Also visit Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. at Booth #313.

Supported by Novartis Pharmaceuticals Corporation

Not For Credit

Presented by:
Bradley E. Chipps, MD

In this presentation, Dr. Bradley Chipps will discuss the multiple pro-inflammatory pathways involved in asthma pathophysiology, reviewing established mediators such as IgE, IL-4/IL-13 and IL-5, as well as covering new science surrounding DP2 as a major regulator of the inflammatory cascade. The presentation will also explore the impact of persistent inflammation on downstream structural effects and, ultimately, clinical manifestations of asthma that remain poorly controlled in many patients.

Also visit Novartis Pharmaceuticals Corporation at Booth #1003.